Evidence map›Paper›PMID 41066723›Full record

ArticleNeurology2025

Core Clinical Features Associated With Survival in Patients With Dementia With Lewy Bodies.

Stuart J McCarter, Tanis J Ferman, Kiera M Grant, Jeremiah Aakre, David S Knopman, Neill R Graff-Radford, Leah K Forsberg, Julie A Fields, Gregory S Day, Toji Miyagawa and 13 more

Abstract read
In one paragraph

Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Stuart J McCarterNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-8158-8835
Tanis J FermanPsychiatry and Psychology, Mayo Clinic, Jacksonville, FL.ORCID 0000-0001-8377-6194
Kiera M GrantBiomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Jeremiah AakreBiomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.ORCID 0000-0002-3517-4153
David S KnopmanNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-6544-066X
Neill R Graff-RadfordNeurology, Mayo Clinic, Jacksonville, FL.ORCID 0000-0001-9847-9096
Leah K ForsbergNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-4086-9598
Julie A FieldsPsychiatry and Psychology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-1282-9866
Gregory S DayNeurology, Mayo Clinic, Jacksonville, FL.ORCID 0000-0001-5133-5538
Toji MiyagawaNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-9387-0253
Rodolfo SavicaNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-2543-0627
Hugo BothaNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-4390-685X
David T JonesNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4807-9833
Vijay K RamananNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-6591-8734
Christian LachnerPsychiatry and Psychology, Mayo Clinic, Jacksonville, FL.ORCID 0000-0002-1801-9768
Aivi T NguyenLaboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-1809-9451
Melissa E MurrayNeuroscience, Mayo Clinic, Jacksonville, FL; and.ORCID 0000-0001-7379-2545
Ronald C PetersenNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-8178-6601
R Ross ReichardLaboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-0842-2462
Dennis W DicksonNeuroscience, Mayo Clinic, Jacksonville, FL; and.ORCID 0000-0001-7189-7917
Kejal KantarciRadiology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-8001-2081
Bradley F BoeveNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4153-8187
Jonathan Graff-RadfordNeurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-2770-0691

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER, Bradley F Boeve · 2019 to 2026
$120.9M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of DiseaseU01NS120901 · NINDS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Stacey Lynn Clardy · 2021 to 2026
$19.6M
Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
The neurobiology of two distinct types of progressive apraxia of speechR01DC014942 · NIDCD · MAYO CLINIC ROCHESTER · PI Keith A Josephs, Rene Lynn Utianski · 2017 to 2026
$4.9M
Bio-RaPID: Biomarkers and Rates of Progression In Dementia.R01AG089380 · NIA · MAYO CLINIC JACKSONVILLE · PI DAY, GREGORY SCOTT · 2024 to 2025
$4.1M
NEUROPSYCHOLOGY OF DEMENTIA WITH LEWY BODIESR01AG015866 · NIA · MAYO CLINIC JACKSONVILLE · PI FERMAN, TANIS JILL · 1999 to 2009
$2.6M
NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG015866NIA NIH HHS R01 AG089380NIA NIH HHS U01 AG057195NIA NIH HHS U19 AG032438NIA NIH HHS U19 AG063911NIDCD NIH HHS R01 DC014942NINDS NIH HHS U01 NS100620NINDS NIH HHS U01 NS120901
6 · The paper itself

Abstract

BACKGROUND AND

objectivesThis analysis used clinical data from prospectively followed participants meeting criteria for probable dementia with Lewy bodies (DLB) in the Mayo Clinic Alzheimer's Disease Research Center (ADRC) between 1998 and 2024. DLB is characterized by unique core features of visual hallucinations (VHs), parkinsonism, REM sleep behavior disorder, and cognitive fluctuations with a variable disease course. DLB is associated with a poor prognosis, but whether these unique DLB core clinical features influence survival is unknown. We aimed to determine whether core clinical features are associated with survival in patients with probable DLB.

methodsPatients followed in the Mayo Clinic ADRC between 1998 and 2024 underwent annual clinical assessments. Those who met clinical criteria for probable DLB were analyzed. Time-dependent Cox proportional hazard models using age as the time scale determined associations between the individual and cumulative number of core clinical DLB features and survival. The prognostic significance of core features present at the time DLB criteria were met was assessed in separate models. Models were adjusted for sex and duration from the onset of cognitive symptoms to DLB diagnosis.

resultsOf 488 patients with probable DLB meeting inclusion criteria, 118 (24%) were women with a mean age of 71.9 ± 8.4 years at the time of meeting probable DLB criteria. Shorter survival was associated with the development of VHs (hazard ratio [HR] 3.25, 95% CI 2.46-4.29) and parkinsonism (HR 2.28, 95% CI 1.54-3.39) during the disease course and VHs at the time of DLB diagnosis (HR 1.60, 95% CI 1.18-2.16). All four core features were also associated with shorter survival (4 core features vs 2 core features, HR 3.58 95% CI 2.66-4.80, 4 core features vs 3 core features, HR 2.46, 95% CI 1.86-3.25). In 191 patients (45 women (24%) with a mean age of 71.2 ± 8.6 years at probable DLB diagnosis) with autopsy-confirmed DLB, VHs, parkinsonism, and all four core features were associated with shorter survival. Sex was not associated with survival. DISCUSSION: VHs, parkinsonism, and the development of all 4 core features were associated with shorter survival in probable and in autopsy-confirmed DLB. These findings have important prognostic and management implications for patients with DLB and their caregivers.

Indexed as

HallucinationsLewy Body DiseaseAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisProspective StudiesREM Sleep Behavior Disorder

Identifiers

PMID41066723
PMCPMC12509705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.